A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer.

Wang ZQ, Qu TR, Zhang ZS, Zeng FS, Song HJ, Zhang K, Guo P, Tong Z, Hou DY, Liu X, Wang L, Wang H, Xu W

Small (Weinheim an der Bergstrasse, Germany)25 Apr 2024Cited by 3 (Europe PMC)

PMID38660815DOI10.1002/smll.202310416PepBankPUB-38660815

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

01AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Mechanism
In bladder cancer experiments, LTX‑315 exposure after TSRP cleavage resulted in CD8 T-cell infiltration.
In plain wordsIn mice, cleavage of the LTX‑315-containing construct resulted in CD8 T-cell infiltration.
Peptide
LTX-315
Outcome
IncreaseCD8 T-cell infiltration
Study
Mousen: not reported in source
Tumor-bearing mice
Outcome group
Immune response · Cancer
Source sentences
Summary
Furthermore, LTX-315 is exposed after TSRP cleavage, resulting in Calreticulin activation and CD8⁺ T cells infiltration.
3 context sentences(design, population, supporting numbers)
Summary · context
All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds.
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081507
02AnimalNot a test of LTX-315 aloneAnimal study (in vivo)Efficacy outcome
In tumor-bearing mice, the processes induced by the LTX‑315-containing TSRP increased survival rate nearly 4-fold.
In plain wordsIn mice with tumors, the LTX‑315-containing construct increased survival rate nearly 4-fold.
Peptide
LTX-315
Outcome
IncreaseSurvival rate
Study
Mousen: not reported in source
Tumor-bearing mice
Outcome group
Mortality · Cancer
Measurements
Survival rate increase
≈ 4 fold
TSRP
Source sentences
Summary
All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081508
03LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In bladder cancer experiments, the LTX‑315-containing TSRP formed membrane nanofibers with retention up to 12 h after receptor binding and cleavage.
In plain wordsIn cells, the LTX‑315-containing construct formed membrane nanofibers that remained for up to 12 hours.
Peptide
LTX-315
Outcome
Not applicableMembrane nanofiber retention
Study
n: not reported in source
Bladder cancer
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Once its binding to FGFR-1, the TSRP could cleaved by MMP-2/9 to form the nanofibers on the cell membrane, with a retention time of up to 12 h.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081501
04LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In bladder cancer experiments, the LTX‑315-containing TSRP suppressed ERK phosphorylation downstream of FGFR-1.
In plain wordsIn cells, the LTX‑315-containing construct reduced ERK phosphorylation.
Peptide
LTX-315
Outcome
DecreaseERK phosphorylation
Study
n: not reported in source
Bladder cancer
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Through suppressing the phosphorylation levels of ERK 1/2 and PI3K/AKT signaling pathways downstream of FGFR-1, the TSRP significant inhibit the growth of tumor cells and the formation of angioginesis.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081502
05LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In bladder cancer experiments, the LTX‑315-containing TSRP suppressed PI3K/AKT pathway phosphorylation downstream of FGFR-1.
In plain wordsIn cells, the LTX‑315-containing construct reduced PI3K/AKT pathway phosphorylation.
Peptide
LTX-315
Outcome
DecreasePI3K/AKT phosphorylation
Study
n: not reported in source
Bladder cancer
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Through suppressing the phosphorylation levels of ERK 1/2 and PI3K/AKT signaling pathways downstream of FGFR-1, the TSRP significant inhibit the growth of tumor cells and the formation of angioginesis.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081503
06LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In bladder cancer experiments, the LTX‑315-containing TSRP significantly inhibited tumor cell growth.
In plain wordsIn cells, the LTX‑315-containing construct inhibited tumor cell growth.
Peptide
LTX-315
Outcome
DecreaseTumor cell growth
Study
n: not reported in source
Bladder cancer
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Through suppressing the phosphorylation levels of ERK 1/2 and PI3K/AKT signaling pathways downstream of FGFR-1, the TSRP significant inhibit the growth of tumor cells and the formation of angioginesis.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081504
07LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In bladder cancer experiments, the LTX‑315-containing TSRP significantly inhibited angiogenesis.
In plain wordsIn lab tests, the LTX‑315-containing construct inhibited blood vessel formation.
Peptide
LTX-315
Outcome
DecreaseAngiogenesis
Study
n: not reported in source
Bladder cancer
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Through suppressing the phosphorylation levels of ERK 1/2 and PI3K/AKT signaling pathways downstream of FGFR-1, the TSRP significant inhibit the growth of tumor cells and the formation of angioginesis.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081505
08LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism
In bladder cancer experiments, LTX‑315 exposure after TSRP cleavage resulted in calreticulin activation.
In plain wordsIn cells, cleavage of the LTX‑315-containing construct activated calreticulin.
Peptide
LTX-315
Outcome
IncreaseCalreticulin activation
Study
n: not reported in source
Bladder cancer
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Furthermore, LTX-315 is exposed after TSRP cleavage, resulting in Calreticulin activation and CD8⁺ T cells infiltration.
2 context sentences(design, population, supporting numbers)
Summary · context
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation;
Summary · context
iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Report a problemFND-3866081506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.